Company profile
Beleave Inc.
OTC: BLEVF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Oakville, ONReports USD
#816 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 25
v0.1 · 5/100 weight · pillars only
↑ Piotroski F, balance-sheet leverage · ↓ market scale, return on equity
Methodology →Revenue TTM
$2.2M
Rev growth YoY (TTM)
+115.2%
Net income (FY)
-$25.8M
Employees
—
as of 2026-07-19
Market cap
$566
as of 2026-07-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.8M2.4M CAD2018
Net income-$25.8M-33.8M CAD2018
Operating income-$17.9M-23.5M CAD2018
Total assets$17.7M23.6M CAD2018
Liabilities$9.9M13.2M CAD2018
Equity$7.8M10.4M CAD2018
Revenue trend
FY2016 – FY2018 · USD
FY16
FY17
FY18
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Beleave Inc.’s revenue?
Beleave Inc. booked $1.8M in FY2018 revenue — among the slowest-growing Healthcare companies we track, at a -1423.0% net margin.
Peers · Healthcare
West Island Brands Inc.——BioRegenx, Inc.30DInnovative MedTech Inc.49DBionik Laboratories Corp.——Nutranomics, Inc.——CanaFarma Hemp Products Corp.——Key facts
CEOVasilios Panagiotakopoulos
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersOakville, ON
ExchangeOTC: BLEVF
Employees—
IPO date2016-09-28
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.